40 terminated. 40 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Terminated 40 |
| Phase 3 | 6 | Terminated 6 |
| Phase 1 | 2 | Terminated 2 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| Study of EQU-001 for Uncontrolled Focal Onset Seizures EQU-001, Matching Placebo - Focal Onset Seizures | Phase 2 | Terminated | Equilibre Biopharmaceuticals B.V. | 27 | 2022-12-27 | 2023-12-21 |
| Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures NBI-921352 - Focal Onset Seizure, Focal Onset Epilepsy | Phase 2 | Terminated | Neurocrine Biosciences | 82 | 2022-11-09 | 2024-04-12 |
| Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE NBI-921352 - SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 8 | 2022-07-12 | 2026-11-13 |
| Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep NBI-827104 - Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | Phase 2 | Terminated | Neurocrine Biosciences | 19 | 2022-06-07 | 2026-02-13 |
| Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) NBI-921352, Placebo - SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 8 | 2022-01-31 | 2025-10-16 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures Lacosamide intravenous, Lacosamide oral, Active Comparator - Electroencephalographic Neonatal Seizures, Epilepsy | Phase 2 | Terminated | UCB Biopharma SRL | 29 | 2021-03-31 | 2025-10-03 |
| Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion Valproic Acid delivered to ICV - Focal Epilepsy | Phase 1 / Phase 2 | Terminated | Cerebral Therapeutics LLC | 20 | 2021-01-01 | 2024-03-13 |
| An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures CVL-865 - Seizures | Phase 2 | Terminated | AbbVie | 105 | 2020-12-08 | 2025-12-11 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC), Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC) - Refractory Epilepsy | Phase 2 | Terminated | Cerebral Therapeutics LLC | 30 | 2020-08-21 | 2024-03-13 |
| A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients JBPOS0101 - Refractory Infantile Spasms | Phase 2 | Terminated | Bio-Pharm Solutions Co., Ltd. | 16 | 2020-04-15 | 2024-08-22 |
| Flunarizine for Treatment Resistant Absence Epilepsy Flunarizine Hydrochloride - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 2 | Terminated | University of British Columbia | 9 | 2019-09-20 | 2023-12-01 |
| A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy Placebo, E2082 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 8 | 2018-10-31 | 2020-09-28 |
| Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Padsevonil - Drug-Resistant Epilepsy, Focal-Onset Seizures | Phase 2 | Terminated | UCB Biopharma SRL | 406 | 2018-08-27 | 2021-12-29 |
| A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy Placebo, E2730 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 6 | 2018-07-27 | 2022-05-04 |
| A Study of Soticlestat in Adults and Children With Rare Epilepsies Soticlestat - Epilepsy, Dravet Syndrome (DS) | Phase 2 | Terminated | Takeda | 156 | 2018-07-19 | 2026-09-04 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 11 | 2018-02-20 | 2023-06-18 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 20 | 2017-12-29 | 2023-07-21 |
| A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS) Radiprodil - Infantile Spasms (IS) | Phase 2 | Terminated | UCB Biopharma S.P.R.L. | 3 | 2017-12-04 | 2019-09-17 |
Showing 20 of 40. Sign in to see all of them.
Seizures (14) · Drug Resistant Epilepsy (7) · Epilepsies, Partial (7) · Epilepsy, Absence (4) · Spasms, Infantile (4) · Epilepsies, Myoclonic (3) · Epilepsy, Reflex (2) · Epilepsy, Temporal Lobe (2) · Leigh Disease (2) · Lennox Gastaut Syndrome (2) · Mitochondrial Diseases (2) · Myoclonic Epilepsy, Juvenile (2) · Status Epilepticus (2) · Acidosis, Lactic (1)
Brain Diseases (40) · Central Nervous System Diseases (40) · Nervous System Diseases (40) · Neurologic Manifestations (17) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Epileptic Syndromes (15) · Epilepsy, Generalized (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Epilepsies, Myoclonic (3) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Carbohydrate Metabolism, Inborn Errors (2)
Cannabidiol (4) · Diazepam (2) · Lacosamide (2) · Acetazolamide (1) · Buspirone (1) · Carvedilol (1) · Cysteamine (1) · Fish Oils (1) · Flunarizine (1) · Immunoglobulins, Intravenous (1) · PF-06372865 (1) · Safflower Oil (1) · alpha-tocotrienol quinone (1) · ezogabine (1) · ganaxolone (1)
Neurocrine Biosciences (4) · UCB Biopharma SRL (3) · Acorda Therapeutics (2) · Cerebral Therapeutics LLC (2) · Eisai Inc. (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Radius Pharmaceuticals, Inc. (2) · AbbVie (1) · Addex Pharma S.A. (1) · Amgen (1) · Bio-Pharm Solutions Co., Ltd. (1) · Biohaven Therapeutics Ltd. (1) · Columbia University (1) · Emory University (1) · Equilibre Biopharmaceuticals B.V. (1)
United States (29) · Australia (8) · Spain (8) · Canada (7) · France (7) · United Kingdom (6) · Belgium (5) · Germany (5) · Poland (5) · Israel (4) · Italy (4) · Hungary (3) · Austria (2) · Bulgaria (2) · Croatia (2)
Ahmed Elkashef, MD (2) · William H Theodore, M.D. (2) · Beverly S Wical, MD (1) · Charles M. Epstein, M.D. (1) · Derek Chong, MD, MSc (1) · Hee Jin Kim (1) · Katherine C. Nickels, M.D. (1) · Lee Min Jae (1) · Mac Burnham, PhD (1)
2008 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)